Paragon Biomedical Report issue

For profit Phase 2 Phase 3
Founded: Irvine CA United States (1989)
Status: Acquired by Clinipace LTD (2012)

Organization Overview

First Clinical Trial
2008
NCT00691964
First Marketed Drug
2013
phenylephrine (Prefrin)
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PARAGON BIOTECK

Active Ingredients

Marketed Drugs (1)

phenylephrine (Prefrin) (2013)

Drugs in Phase 3 Trials (2)

briakinumab (2 trials)

etanercept (enbrel) (2 trials)

Drugs in Phase 2 Trials (1)

np2 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pain, Intractable (Phase 2)

Psoriasis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3